ferryman - please. you whine and you whine and you whine, to what end? are you just trying to irritate everyone on this board with your droning on and on about dilution?
investor conference tomorrow, 10:25 am might not amount to much but any investor interested in XOMA will want to know about the GS loan issues and why its not done yet.( it's been about a month since CEO ENGLE stated that GS loan should be resolved)
CEO could surprise everyone with some news timed to the conference or it could just be more of the same .
i do believe that the company wants the stock price higher so i would expect some positive progress to be announced ( could be Higher than expected CIMZIA royalties, GS loan resolution or XOMA O52 partner progress or even additional gov't payments for vaccine work)
conference is not really fluff, ALAN GREENSPAN is the keynote speaker and its in New York so we could expect serious investors to be watching.http://www.rodm.com/conferences?id=30
http://www.xoma.com/company/news-events/press-releases/index.cfm?releaseID=407136 BERKELEY, Calif., Sept. 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven Engle, Chairman and Chief Executive Officer, is scheduled to present at the following conferences in September 2009:
Rodman &; Renshaw 11th Annual Healthcare Conference, New York City: September 10, 10:25 am EDT
BioCentury NewsMakers in the Biotech Industry Conference, New York City: September 16, 9:25 am EDT
Live and archived webcasts of these presentations will be available via the Investors tab of the XOMA website, www.xoma.com.
About XOMA
XOMA discovers, develops and manufactures antibody therapeutics designed to treat inflammatory, autoimmune, infectious and oncological diseases. The company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody entering Phase 2 development, and XOMA 3AB, a biodefense anti-botulism antibody candidate.
XOMA has world-leading capabilities in antibody engineering and formulation, including a unique collection of antibody phage display libraries and expertise in the rapid construction of large novel libraries. Access to multiple libraries may offer a number of benefits to XOMA, its partners and licensees because it enables the use of libraries best suited to the needs of a particular discovery project. This increases the probability of technical and business success in finding rare and unique functional antibodies directed to targets of interest.
XOMA's proprietary technology platform also includes Targeted Affinity Enhancement(tm) for rapid, focused antibody affinity maturation, Human Engineering(tm) for antibody humanization and its widely-licensed bacterial cell expression and manufacturing technologies which have been licensed to more than 50 companies.
XOMA's multiple revenue streams result from the licensing of its antibody technologies, product royalties, development collaborations and biodefense contracts. XOMA's technologies team have contributed to the success of marketed antibody products, including LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of approximately 190 employees at its Berkeley, CA location. For more information, please visit href="http://www.xoma.com." rel="nofollow" target="_blank">http://www.xoma.com.>
Market Data 
Markets 
AI
